Immunic closed a $400 million private placement financing to support Phase 3 trials in multiple sclerosis and transition to a commercial neurology company.
2
Small molecules remain crucial in targeting intracellular pathways, particularly in conditions like multiple sclerosis, due to their practical advantages.
3
Early small-molecule discovery is accelerating through AI and advanced screening technologies, enhancing the efficiency of candidate identification.
4
Drug development faces complexity from stringent clinical trial requirements and evolving regulations, necessitating smarter trial designs and better data use.
5
Expanding biomarker-based trial endpoints could streamline drug approvals, reduce costs, and enhance competition in pharmaceutical research and development.
